A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment

PHASE3CompletedINTERVENTIONAL

Enrollment

974

Participants

Timeline

Start Date

May 31, 2001

Study Completion Date

November 30, 2003

Conditions

DementiaAlzheimer Disease

Interventions

DRUG

Galantamine hydrobromide

All Listed Sponsors

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00236574 - A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment | Biotech Hunter | Biotech Hunter